3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Ovarian Neoplasms
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Ovarian Epithelial
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Temozolomide
30
Radiotherapy
23
Filgrastim
12
Carmustine
12
Irinotecan
11
Carboplatin
11
Chemotherapy, Adjuvant
9
O(6)-benzylguanine
8
Etoposide
7
Surgical Procedures, Operative
6
Magnetic Resonance Spectroscopy
6
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Granulocyte Colony-Stimulating Factor
5
Cyclophosphamide
5
sargramostim
4
motexafin gadolinium
4
Topotecan
4
Thiotepa
4
Paclitaxel
4
Melphalan
4
Gene Expression Profiling
4
Gemcitabine
4
Drug Therapy
4
Busulfan
4
temsirolimus
3
etoposide phosphate
3
Specimen Handling
3
Mass Spectrometry
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Central Nervous System Neoplasms
×
interferon gamma-1b
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled